Clinical Trial Update: EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Completed Phase 2 clinical trial evaluating EF5 as a marker of tumor hypoxia in patients with stage I-III non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EF5

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma | Phase 2 | Status: COMPLETED